CovenD24 (EXO-CD24) / Tel Aviv Sourasky Medical Center, OBCTCD24 - LARVOL DELTA

The safety and potential efficacy of exosomes overexpressing CD24 (EXO-CD24) in mild-moderate COVID-19 related ARDS. (PubMed, Respir Res) - "EXO-CD24 presents a promising therapeutic approach for hyper-inflammatory state and in particular ARDS. Its unique combination of exosomes, as a drug carrier, and CD24, as an immunomodulator, coupled with inhalation administration, warrants further investigation in a larger, international, randomized, quadri-blind trial against a placebo."

Journal • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases • CD24 • CRP • IL10

Inhaled CD24-Enriched Exosomes (EXO-CD24) as a Novel Immune Modulator in Respiratory Disease. (PubMed, Int J Mol Sci) - "Herein, the safety and efficacy of mEXO-CD24 is shown in murine models of several pulmonary diseases (sepsis, allergic asthma, Chronic Obstructive Pulmonary Disease(COPD), fibrosis). EXO CD24 can suppress the hyperinflammatory response in the lungs in several pulmonary diseases with a significant unmet need for treatment options."

Journal • Acute Respiratory Distress Syndrome • Asthma • Chronic Obstructive Pulmonary Disease • Fibrosis • Immunology • Infectious Disease • Inflammation • Pulmonary Disease • Respiratory Diseases • Septic Shock • CD24

Inhaled Exosomes Genetically Manipulated to Overexpress CD24 (EXO-CD24) as a Compassionate Use in Severe ARDS Patients. (PubMed, Biomedicines) - "EXO-CD24 holds promise as a potential therapeutic agent for all stages of ARDS, even in severe intubated cases. Importantly, EXO-CD24 demonstrated a favorable safety profile without any apparent side effects with promising efficacy. Furthermore, the potential of EXO-CD24 as a platform for addressing hyper-inflammatory states warrants exploration. Further research and larger-scale clinical trials are warranted to validate these preliminary findings."

Journal • Acute Respiratory Distress Syndrome • Cardiovascular • Coronary Artery Disease • Diabetes • Heart Failure • Hypertension • Infectious Disease • Influenza • Metabolic Disorders • Novel Coronavirus Disease • Oncology • Pulmonary Disease • Respiratory Diseases • Septic Shock • Transplantation • CD24 • CRP

Safety and Efficacy of EXO-CD24 in Preventing Clinical Deterioration in Patients With Mild-Moderate ARDS (clinicaltrials.gov) - P2b | N=90 | Recruiting | Sponsor: Nano24med

New P2b trial • Acute Respiratory Distress Syndrome

Safety and Potential Efficacy of Exosomes Overexpressing CD24 (EXO-CD24) for the Prevention of Clinical Deterioration in Patients with Moderate or Severe COVID-19: A Phase II, Randomized, Single-blinded Study. (IDWeek 2022) - No abstract available

Clinical • P2 data • Infectious Disease • Novel Coronavirus Disease • CD24

A novel platform for attenuating immune hyperactivity using EXO-CD24 in Covid-19 and beyond. (PubMed, EMBO Mol Med) - "EXO-CD24 effectively reduced inflammatory markers and cytokine/chemokine, though randomized studies are required. EXO CD24 may be a treatment strategy to suppress the hyper-inflammatory response in the lungs of Covid-19 patients and further serve as a therapeutic platform for other pulmonary and systemic diseases characterized by cytokine storm."

Journal • Immune Modulation • Infectious Disease • Inflammation • Novel Coronavirus Disease • CD24

A clinical trial for the safety and efficacy of exosomes that overexpress CD24 for preventing the deterioration of moderate or severe COVID-19 (clinicaltrialsregister.eu) - P2 | N=156 | Ongoing | Sponsor: OBCTCD-24 Ltd

New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Biomedical application of small extracellular vesicles in cancer treatment. (PubMed, Adv Drug Deliv Rev) - "Finally, we present an overview of the different chimeric EVs developed in the last few years, demonstrating that they can be conjugate to nanoparticles, biomolecules, cancer drugs, etc., and can be developed for a specific cancer treatment. Additionally, we summarized the clinical trials where EVs are used in the treatment of several cancer types aiming to improve the prognosis of these deadly diseases."

Journal • Review • Oncology

"מישהו בפיד יודע מה עלה בגורלה של התרופה שפותחה באיכילוב EXO-CD24? בפעם האחרונה ששמעתי עליה, היא הייתה ב phase3 ביוון והשיגה תוצאות מעולות. היו התפתחויות עם זה? @erlichya @segal_eran" (@ShyEngelberg)

P3 data • CD24

"a co z Izraelskim EXO-CD24 ?" (@Endrjulotson)

CD24

A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection (clinicaltrials.gov) - P2; N=155; Active, not recruiting; Sponsor: Eli Sprecher, MD

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease • CD24 • IL6 • PCR

Safety and Efficacy of Exosomes Overexpressing CD24 in Two Doses for Patients With Moderate or Severe COVID-19 (clinicaltrials.gov) - P2; N=90; Recruiting; Sponsor: Athens Medical Society; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • PCR

A study for patients with moderate or severe COVID-19 for the evaluation of the safety and efficacy of a new investigational drug using exosomes (clinicaltrialsregister.eu) - P2; N=90; Ongoing; Sponsor: Athens Medical Society

New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IL6 • PCR

Israeli breakthrough COVID treatment gets approval for advanced trial (The Jerusalem Post) - "A coronavirus treatment...has been approved by the Health Ministry for a Phase II/III trial...EXO-CD24 COVID-19 treatment will soon launch a double-blind placebo trial in which around 150 patients in moderate or serious condition will be treated with the medication....Sourasky will partner with other medical centers throughout the country, Arber said, and will likely extend the trial to other countries...The hospital is in dialogue with India, Brazil, Portugal, Costa Rica and the Czech Republic about getting approval to run trials there...The treatment is being tested in Greece in what is known as a dosing study to determine how much is needed to most effectively treat COVID-19."

New P2/3 trial • Trial status • Infectious Disease • Novel Coronavirus Disease

Safety and Efficacy of Exosomes Overexpressing CD24 in Two Doses for Patients With Moderate or Severe COVID-19 (clinicaltrials.gov) - P2; N=90; Not yet recruiting; Sponsor: Athens Medical Society

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease • PCR

New Israeli drug cured 29 of 30 moderate/serious COVID cases in days — hospital (The Times of Israel) - P1, N=30; "A new coronavirus treatment being developed at Tel Aviv’s Ichilov Medical Center has successfully completed phase 1 trials and appears to have helped numerous moderate-to-serious cases of COVID-19 quickly recover from the disease...EXO-CD24 substance had been administered to 30 patients whose conditions were moderate or worse, and all 30 recovered — 29 of them within three to five days....The medicine will now move on to further trial phases..."

Cytokine storm • P1 data • Infectious Disease • Novel Coronavirus Disease

Feeling better ‘in 2 hours’: COVID drug for critically ill starts Phase 3 trials (The Times of Israel) - "Allocetra treats the over-response of the immune system and inflammatory response that is sometimes seen in COVID-19 patients, called a cytokine storm....The drug is now entering Phase 3 trials and will be given to over 100 people....Tel Aviv’s Ichilov Medical Center claimed a 'huge breakthrough' on Friday, saying that Prof. Nadir Arber’s EXO-CD24 inhaled medicine had been administered...He has applied to the Health Ministry to start a Phase 2 trial."

Cytokine storm • New P2 trial • New P3 trial • Infectious Disease • Novel Coronavirus Disease